ALKtALK with Dr. Alex Spria

Inside the Pipeline: TRI-611 and ALK+ Treatment Strategies

In this ALKtALK, we’re joined by Alexander Spira, MD, PhD, FASCO, medical oncologist at Virginia Cancer Specialists and member of the ALK Positive Scientific Advisory Board.

Dr. Spira shares insights and expertise on two clinical trials for ALK-positive patients—TRI-611 and Gilteritinib—and what they may mean for the ALK-positive community. Drawing on his experience as a leading thoracic oncologist involved in advancing clinical research and treatment strategies, he offers valuable perspective on the evolving landscape of ALK+ care.

This conversation also includes a community Q&A, with thoughtful questions from patients and care partners.

ALKtALKs bring our community together with leading experts so patients and care partners can stay informed and empowered through shared knowledge and conversation.

▶️ Watch now to learn more about emerging ALK+ clinical trials and what’s on the horizon.

#ALKPositive #ALKtALK #LungCancerResearch #MoreResearchMoreTime